Sign inJoin waitlistJoin the waitlist

EB

Ellin Berman

Attending Physician · New York Presbyterian Hospital

Credentials: · · · · ·

History

New York Presbyterian Hospital
Present

Hematology and Medical Oncology
Memorial Sloan Kettering Cancer Center
1980–1983
Internal Medicine
Boston University Medical Center
1977–1980
Harvard Medical School
1973–1977

Research

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
New England Journal of Medicine · 2019 · 1,078 citations
Leukaemogenesis induced by an activating β-catenin mutation in osteoblasts
Nature · 2014 · 438 citations
Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous…
Blood · 1991 · First of over 10 authors · 372 citations

SK
Sanford Kempin
16 papers
BS
Bruce Smith
12 papers
DS
David Snyder
11 papers
Joseph Moore
11 papers
Michael Andreeff
11 papers
Daniel DeAngelo
10 papers
Jerald Radich
10 papers
MT
Martin Tallman
10 papers
Jessica Altman
9 papers
MT
Moshe Talpaz
9 papers
MW
Meir Wetzler
8 papers
Neil Shah
8 papers

Grants

Effect of Tamoxifen on Reversing the Mdr Phenotype
National Cancer Institute · R01
Contact PI · $180.8K · Sloan-Kettering Inst Can Research
1990–1993

Clinical trials

Effect of Imatinib on Bone Metabolism in Patients With Chronic Myelogenous Leukemia or Gastrointestinal Stromal Tumors
Principal investigator · Completed
Memorial Sloan Kettering Cancer Center
2006–2013
Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Principal investigator · Completed · Phase 1, Phase 2
Memorial Sloan Kettering Cancer Center
2003–2005
Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
Study chair · Completed · Phase 2
Memorial Sloan Kettering Cancer Center
2002–2003